ASCO 2023: Focus on Myelofibrosis

Rob DillardASCO 2023 | September 5, 2023
A study aimed to validate the use of the Molecular International Prognostic Scoring System for myelodysplastic syndromes.
Read More
Rob DillardASCO 2023 | September 26, 2023
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Rob DillardASCO 2023 | August 30, 2023
The bone marrow microenvironment of myelodysplastic syndromes is very different from that of acute myeloid leukemia.
Rob DillardASCO 2023 | June 22, 2023
Middle meningeal artery embolization is a novel, minimally invasive strategy that may help manage subdural hematomas in AML.
Rob DillardASCO 2023 | August 30, 2023
Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes.
Dr. Ruben MesaASCO 2023 | September 26, 2023
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Rob DillardASCO 2023 | August 25, 2023
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Rob DillardASCO 2023 | September 26, 2023
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
Rob DillardASCO 2023 | August 25, 2023
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Rob DillardASCO 2023 | September 26, 2023
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
Rob DillardASCO 2023 | August 28, 2023
US veterans who were exposed to Agent Orange have an increased risk of myeloproliferative neoplasms.
Rob DillardASCO 2023 | September 26, 2023
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
Rob DillardASCO 2023 | September 26, 2023
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Rob DillardASCO 2023 | August 28, 2023
Patients admitted for atrial fibrillation who have myeloproliferative neoplasms have an increased risk of bleeding.
Advertisement
Advertisement
Latest News

February 28, 2024